The cycle of Survival is proud to provide key funding to support the discovery of brain cancer drugs at the US National Institute of Neurological Disorders and Stroke (NORTH) The program is pursuing a number of leading research initiatives aimed at expanding access to new treatments for brain cancer survivors and their families. Working with the National Institutes of Health (NIH) and other federal, state, and local agencies, the NOR North Program will play a key role in bringing new concepts and scientific discoveries from the lab to patients who need them. Because drug development associated with brain tumors, such as the development of new cancer drugs, is slow, speeding up the process of turning lab discoveries into life-saving treatments is critical to these patients “survival.
Brain cancer remains the second most common cancer in the US and the third leading cause of death among young adults aged 20 to 39. By 2020, pancreatic cancer is projected to be the leading cause of death among young people between the ages of 20 and 39, and brain tumors will continue to be the fourth most common cancer in this age group, according to the US Centers for Disease Control and Prevention.
Among those who survive three years after diagnosis, there is a high morbidity and mortality rate, with those who survive suffering severe lifelong disabilities despite the life-saving therapies they receive. There are a number of areas where survival and quality of life can be improved through the novel, targeted therapies that have been used since diagnosis.
Many childhood brain tumors, caused by genes that play a significant role in brain development, were previously caused not only by cancer, but also by a range of other diseases such as Alzheimer’s, Parkinson’s, diabetes, and heart disease. More than 1,000 people who have survived brain cancer will be screened as part of a three-year research project funded by the Morrison government.
Nearly 2,000 Australians are diagnosed with brain cancer each year, which has a high morbidity and mortality rate and is responsible for more than 20 percent of all cancer deaths in Australia and almost one in four cancer deaths. A team of researchers from the University of Sydney has been awarded $4.97 million to conduct a comprehensive review of the current state of research on brain tumors to reflect the impact on patients, their families, and carers. Immediately improving research will lead to improved models of coordinated care that benefit not only patients and their families, but also the general public.
A second research team has received $1.94 million from the University of New South Wales to help survivors of childhood brain tumors improve their health and improve the quality of life of their families and caregivers. Nearly half of all children and young adults in Australia have health problems after completing cancer treatment, according to the Australian Cancer Council.
The research program will put together a tailor-made care package for survivors, including telemedicine and care advice, as well as access to health services such as physiotherapy, occupational therapy, and physiotherapy.
The National Cancer Institute (NCI) has announced plans to reshape the way patients and oncologists learn and find information about cancer clinical trials. The first phase will allow cancer data to be hosted on cancer.gov and accessed directly through an Application Programming Interface (API). The aim is to ensure that patients and their treatment teams have access to the information they need at the right time and to increase participation in cancer research studies in order to accelerate the medical discovery and treatment of cancer. Clinical research studies that make up a significant portion of the total number of cancer studies in the United States.
By joining forces in a coordinated effort, the new projects will improve our understanding of the mechanisms that lead to cancer development and accelerate the development of promising therapies that are more effective and less toxic. This method searches for the genes of patients that can lead to cancer, as well as their genetic predispositions for the disease.
This initial collaboration will focus on the most common types of brain cancer in the US and will make the data publicly available to the research community. As we reach more cancer patients at the VA and DoD, we will extend these efforts to other cancers to provide scalable knowledge to physicians who treat more than 1.5 million patients with diagnosed cancers each year.
Alex’s Lemonade Stand Foundation (ALSF) has committed to doubling its investment in brain cancer research by $150 million over the next five years.
Tumor Research Information Inc. is a 501 (c) (3) non-profit organization dedicated to providing emotional and financial support, education, and advocacy to brain tumor patients and raising money for brain tumor research. We provide newly diagnosed brain cancer patients with detailed information, resources, and support by phone and email. The money from Alex’s Lemonade Stand Foundation – which raises funds – supports research and education for newly diagnosed cancer survivors and their families.